Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
Authors:
- Yasser SakrYSYasser Sakr
- the UAE-Jena Research GroupTGthe UAE-Jena Research Group
- Ghazala BelhajGBGhazala Belhaj
- Khaled M. AfetKAKhaled M. Afet
- Dnyanwshwar MundeDMDnyanwshwar Munde
- David MonkDMDavid Monk
- Samuel BuschbeckSBSamuel Buschbeck
Open Access
- 12 April 2021
- journal article
- letter
- Published by Springer Nature in Intensive Care Medicine
- Vol. 47 (6) , 707-709
Abstract
No abstract availableFunding Information
- Universitätsklinikum Jena
This publication has 5 references indexed in Scilit:
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityEBioMedicine, 2021
- Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First ObservationCritical Care Explorations, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2Journal of Virology, 2013
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus EntryJournal of Virology, 2012